Davita Inc vs Standard Lithium Ltd — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Standard Lithium Ltd trades at $1.62 (market cap $409.74M). The key difference: Davita Inc is far larger — about 27.5× Standard Lithium Ltd's market cap, and Davita Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Standard Lithium Ltd for 23 Days on average.
| DVA | SLI | |
|---|---|---|
Market Cap | $11.28B | $409.74M |
Volume | 650,294 | 1,266,140 |
Sector | Health | Basic Materials |
52-Week High | $240.96 | $5.65 |
52-Week Low | $103.87 | $1.61 |
Typical Hold Time | 113 Days | 23 Days |
Enterprise Value | $24.00B | $272.66M |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Standard Lithium (SLI) trades at $1.65, down 4.62% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported no revenue in 2025 and negative net income of -$48.40M, though recent quarters show improving EPS trends with two consecutive beats. Key developments include progress toward a final investment decision for the South West Arkansas lithium project by end-2026 and new customer offtake agreements.
The stock presents high-risk, high-reward potential with 100% analyst buy ratings and a $3.83 consensus price target offering 132% upside. However, significant execution risks remain as the company transitions to commercial production, with negative cash flow from operations and substantial capital requirements ahead.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →